Bollard Group LLC Buys Shares of 17,191 Insmed, Inc. $INSM

Bollard Group LLC bought a new stake in Insmed, Inc. (NASDAQ:INSM) during the second quarter, Holdings Channel.com reports. The fund bought 17,191 shares of the biopharmaceutical company’s stock, valued at approximately $1,730,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Cetera Investment Advisers lifted its position in Insmed by 103.7% during the first quarter. Cetera Investment Advisers now owns 20,679 shares of the biopharmaceutical company’s stock valued at $1,578,000 after buying an additional 10,525 shares during the period. LPL Financial LLC raised its holdings in shares of Insmed by 56.3% during the 1st quarter. LPL Financial LLC now owns 51,213 shares of the biopharmaceutical company’s stock worth $3,907,000 after acquiring an additional 18,456 shares in the last quarter. US Bancorp DE raised its position in shares of Insmed by 18.8% during the 1st quarter. US Bancorp DE now owns 11,323 shares of the biopharmaceutical company’s stock valued at $864,000 after buying an additional 1,790 shares in the last quarter. Atria Wealth Solutions Inc. bought a new stake in Insmed during the first quarter worth approximately $423,000. Finally, Vanguard Group Inc. increased its stake in Insmed by 0.3% during the first quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company’s stock worth $1,393,675,000 after acquiring an additional 49,149 shares during the last quarter.

Insider Activity

In related news, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the firm’s stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $145.45, for a total transaction of $11,129,834.00. Following the completion of the sale, the insider directly owned 36,461 shares of the company’s stock, valued at approximately $5,303,252.45. This trade represents a 67.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Elizabeth M. Anderson sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $195.87, for a total transaction of $1,958,700.00. Following the completion of the transaction, the director directly owned 63,729 shares of the company’s stock, valued at $12,482,599.23. This represents a 13.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 233,650 shares of company stock worth $41,063,785. Insiders own 3.00% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a report on Wednesday, October 8th. TD Cowen lifted their price objective on shares of Insmed from $223.00 to $231.00 and gave the stock a “buy” rating in a research note on Thursday, November 20th. Evercore ISI reissued an “outperform” rating and issued a $180.00 target price on shares of Insmed in a research note on Wednesday, October 1st. Cowen reissued a “buy” rating on shares of Insmed in a research report on Thursday, November 20th. Finally, Wells Fargo & Company boosted their target price on Insmed from $171.00 to $217.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $187.89.

Insmed Price Performance

Shares of INSM stock opened at $204.00 on Friday. The stock has a market capitalization of $43.51 billion, a price-to-earnings ratio of -32.96 and a beta of 1.01. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $212.75. The stock has a fifty day simple moving average of $180.50 and a two-hundred day simple moving average of $134.95.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The company had revenue of $142.34 million for the quarter, compared to the consensus estimate of $114.33 million. During the same period in the previous year, the business earned ($1.27) EPS. Insmed’s revenue for the quarter was up 52.4% compared to the same quarter last year. On average, analysts predict that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.